Detalhe da pesquisa
1.
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Proc Natl Acad Sci U S A
; 118(26)2021 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34172583
2.
Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies.
Pharmaceutics
; 13(9)2021 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34575469
3.
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Cancer Immunol Res
; 9(12): 1451-1464, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635485
4.
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice.
Theranostics
; 10(13): 5815-5828, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32483421
5.
Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue.
Clin Cancer Res
; 26(15): 3999-4009, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31953313